The Use of Gastrografin in Chronic Radiation Enteropathy With Small Bowel Obstruction
NCT ID: NCT03642288
Last Updated: 2018-08-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
112 participants
INTERVENTIONAL
2014-04-01
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Stereotactic Body Radiotherapy for Oligometastases From Colorectal Cancer
NCT02909114
Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal Cancers
NCT01445327
Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma
NCT02193594
A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.
NCT06349044
CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC
NCT06665087
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CRE-induced SBO
Patients with CRE-induced SBO received GG challenge.
Gastrografin
Patients with CRE-induced SBO or ASBO both received GG challenge.
ASBO
Patients with adhesive SBO (ASBO) received GG challenge.
Gastrografin
Patients with CRE-induced SBO or ASBO both received GG challenge.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Gastrografin
Patients with CRE-induced SBO or ASBO both received GG challenge.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* radiation therapy completed at least 6 months before enrolment.
Exclusion Criteria
* large bowel obstruction;
* with a known history of either allergy or hypersensitivity to iodinated contrast agents;
* with signs of strangulation;
* metastatic disease;
* obstruction within 4 weeks after a recent operation or serious comorbidity.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jinling Hospital, China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ding Chao
Clinical Doctor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Gastrografin-CRE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.